

Life Science Wealth

BROUGHT TO YOU BY CONTRARIAN WEALTH COALITION



November 2013

Life Stem Genetics is Now at the Forefront of the Biggest Evolution in the Medical Treatment of Chronic Diseases

Buying **LIFS** now is like owning early shares in the **Fountain of Youth**

The Global Market for Treatment of Chronic Disease: **\$TRILLIONS**



Formerly Incurable... **NOW TREATABLE!**



Degenerative Injuries... **NOW REVERSIBLE!**



The crucial component to enabling a worldwide benefit from stem cell therapy is now ready:

Life Stem Genetics (LIFS)

Life Stem Genetics can fulfill the promise of Adult Stem Cell Therapies and guarantee a higher quality of life to the world!

How high can **LIFS** shares move from here? There is no limit and you can be certain it will be many multiples higher than the current **LIFS trading level near \$1**. Now is the time to buy.

**The Promise of Anti-Aging...
NOW A REALITY!**

[TAKE ADVANTAGE OF OUR PROPRIETARY BUY-STRATEGY](#)

Harvard » Bill Gates Foundation » Nobel Prize Laureates

**Have Joined the Evolution with
LIFE STEM GENETICS**
...to give the World Self-Healing



Scott Fraser, Editor
The Natural Contrarian

We eliminate the vast majority of speculative stocks from our Contrarian investment consideration based on "preemptive assessment" of the risks encountered long before we reach the Vital Event that rewards the early shareholders.

Our Formula
→ **simplified:**

→ Risk is essential to the high reward of speculative stocks


→ Risk can be substantially reduced by our Situational Filters

→ Risk properly assessed reveals the path to high shareholder reward

Our Formula
→ **now applied:**

Life Stem Genetics (LIFS) is now a BUY

Our exclusive Profit-Stock Advisories begin with a breaking Compass Signal



The stakes are too high for Big Pharma and the traditional Healthcare providers to hesitate about the current technology lead maintained by innovators like Life Stem Genetics (LIFS). It makes sense for the Bigs to simply open their acquisition check books rather than try and play catch-up!

Life Stem Genetics (LIFS) is at the forefront of the greatest advancement of Life Science in the history of mankind. Propelled by the world's most powerful institutions, Adult Stem Cell (ASC) therapies will enable all peoples of the world to heal themselves. Life Stem has already applied over 5,000 ASC treatments.

The Powers behind the Evolution

The amount of academic, financial and leadership strength pushing Adult Stem Cell therapies forward is relatively equivalent to that of the Age of Imperialism as the European powers became an irresistible force to colonize the "New World." This time around, with the inevitable expansion of life sciences based on stem cells, all peoples of the world will benefit.

Harvard University holds its status as the proverbial *center of the universe* for stem cell research in the United States. Regenerative biologist and co-founder of the Harvard Stem Cell Institute, Dr. Douglas Melton is leading Harvard's ascendancy to world leadership in the stem cell field. Also important is Dr. Melton's close ties with the Howard Hughes Medical Institute and its deep funding prowess.

The Bill and Melinda Gates Foundation, through its Global Alliance for Vaccines and Immunizations, is

brought directly to YOU followed by precise **Buy, Hold, and Sell** instructions that keep you on the profit-path. On page 15 of this Special Report, please find YOUR personal ticket to joining our exclusive Contrarian Wealth Coalition where you can start exploiting each stock market situation for YOUR OWN personal wealth accumulation.

working toward the acceleration of **new stem cell technologies** coupled with increased access to vital medical treatments in poorer nations. Dr. Orin Levine, formerly of Johns Hopkins, is the foundation's director of stem cell delivery. The strong financial backing of industry titans, such as the founder of Microsoft, provides the crucial monetary fuel for Dr. Levine's mission of saving children's lives.

Recent Nobel Prize Laureates, Sir John Bertrand Gurdon and Shinya Yamanaka, are unifying the academic powerbases of Europe and Asia in accord with America's drive for globalizing Adult Stem Cell therapies. From Cambridge to Kyoto respectively, Gurdon and Yamanaka are making great strides in Adult Stem Cell science in unanimity with our National Institute of Health's Center for Regenerative Medicine.

Life Stem Genetics is delivering the life-giving therapy now that can put Big

**\$TRILLION Pharma out of business!
But wait...**

Big Pharma is getting into Life Stems' business - here's what to watch for:

- Pfizer's Neusentis team developing Regenerative Medicine Portfolio
- GE Healthcare's expanding Life Sciences division on stem cells
- Life Stem's advance technology with micro-cap is buy-out bait!

Begin accumulating LIFS now and watch for the reactive market frenzy!

BUY-ALERT




Company: **Life Stem Genetics**
Symbol: **LIFS**
Initial Buy: **IMMEDIATELY**
Secondary Buy: **\$2 to \$5**
Long Term Target: **\$ Infinite***

*** Because the projected return on investment of the global stem cell industry is already in the \$Billions, I'll wait to put a specific price target on Life Stem Genetics (LIFS) so I don't have to keep raising it. Now is the time to make your initial buy on LIFS. Our initial valuation of Life Stem's future market share is well above the current near \$1 price level and increasing.**

Just above \$1 a share, Life Stem Genetics (LIFS)
Can Become a Major Player in a Market that's Projected to Surpass

\$75 BILLION NEXT YEAR!





HERNIM THE BIG PICTURE

HERE'S THE BIG PICTURE

Adult Stem Cell Therapies are proving highly successful at treating a wide array of neurological disorders, spinal cord and orthopedic injuries, as well as improving overall health and longevity as we age. **The human body has an unparalleled ability to heal itself – far greater than any pharmaceutical or manufactured treatment ever made. Thus, it's no wonder that the proverbial fountain of youth would be found in our OWN STEM CELLS, which, by the way are available in near limitless quantities!**


ZERO CONTROVERSY!

FACT

Adult Stem Cells should NOT be confused with embryonic stem cells, which are highly controversial and regulated.

Naturally, you are the rightful owner of your own stem cells and thus it is your right to be treated with them.

Life Stem Genetics (LIFS) makes that possible.



REVOLUTIONIZE AGING

Stem cells are in many respects the very foundation of what it is to be human. As you're born and begin to grow, stem cells play a vital role in the generation of new replacement cells and tissues as well as in healing and repair.





Whenever a body part or tissue becomes diseased or injured, the brain sends out chemical signals that attract stores of adult stem cells that reside in our fat, blood, tissues, and bone marrow. Our stem cells are able to morph into the cells of countless organs and structures within our own bodies. Through a process called cell division, our stem cells are able to multiply indefinitely resulting in the effective restoration of damaged structures and the rejuvenation of failing cells.


The medical applications of ASC therapies are limitless – and that's why this stock opportunity is so huge. An early investment in Life Stem Genetics (**LIFS**) could prove life-changing in more ways than one!

Get on the "smartmoney" train now...

THIS COULD BE GLOBAL!

Life Stem (LIFS) is at the forefront of a groundbreaking medical therapy that could:

- Save countless lives
- Save \$Billions in medical costs
- Drive LIFS shares many multiples higher!



Keep in mind that the "self-harvesting" of your own Adult Stem Cells (ASC's) for treating YOU is actually nothing new. It's been around for decades with roughly 1 million patients in the U.S. alone being successfully treated via ASC's since the mid-1980's.



State of the Art: Life Stem's treatment facilities offer a spa-like setting where patients undergo a 4-hour ASC treatment. Each clinic can generate up to \$30 MILLION per year in revenues!

WHAT IS NEW...

is the "methodology" in which Adult Stem Cells are being self-harvested and then re-injected into the patient – either intravenously or via direct injection into the afflicted area.

Life Stem Genetics (LIFS) is my #1 pick for expansive shareholder gains as the company begins setting up ASC clinics all over the world utilizing its innovative Adult Stem Cell Self-Harvesting approach. Best of all, since the stem cells being used are your own, there's zero risk of your body rejecting the treatment! The same cannot be said for embryonic stem cell procedures.

LIFE STEM'S EXPERT TEAM

Life Stem's specialists have



Life Stem's specialists have already successfully treated many of the biggest names in Major League Baseball, NFL, NBA, PGA as well as a recent Presidential candidate.




4-time MVP quarterback **Peyton Manning of the Denver Broncos** - following a combination of surgery and Adult Stem Cell therapy on damaged nerves in his neck - is currently having one of the best statistical years on record for any NFL quarterback!

4-time MVP Peyton Manning recently underwent an Adult Stem Cell therapy on his neck. He's now having one of the most productive seasons of his illustrious 15-year NFL career!


And keep in mind that sports injuries and anti-aging are really just the **tip of the iceberg** in terms of the medical reach for Adult Stem Cell therapies. Some of the top thinktanks in medical science are now focusing their research on the potential for Adult Stem Cells to eradicate some of the worst diseases known to mankind including cancer, Alzheimer's, and AIDS.

Funding for this research continues to grow through deep-pocketed sources such as the Howard Hughes Medical Institute and the Bill and Melinda Gates Foundation. Stem Cell therapies may also prove instrumental in treating the millions of people suffering from full or partial paralysis as a result of spinal cord injuries.

As just one example, StemCells, Inc. recently announced that the FDA has authorized an Investigational New Drug (IND) application for clinical testing of stem cells as a treatment for spinal cord injury.



Adult Stem Cell therapies are gaining momentum in the treatment of spinal cord injuries.



Life Stem only harvests cells from your own abdominal fat (or adipose tissue), which contains at least 500 times more "mesenchymal" stem cells than bone marrow. These mesenchymal cells are key because they are able to differentiate into all the various types of tissues, and they do this automatically via cell receptors that facilitate migration to the injured, damaged, or diseased tissue locations within your body!

"This IND is a significant step forward for our spinal cord injury program. With regulatory authorization from Switzerland, Canada and now the United States,

we have the first international trial of a stem cell therapy for spinal cord injury."

— Stephen Huhn, MD, FACS, FAAP,
Vice President, CNS Clinical Research at StemCells, Inc.

The bottom line is that **Life Stem Genetics (LIFS)** is in the right place » Adult Stem Cell therapies » at the right time for astute investors » around \$1 per share!

That's why I'm urging my readers to **JUMP ON THIS ONE IMMEDIATELY** before Wall Street drives LIFS above our current buy-ceiling.

LIFE STEM'S STOCK IS ON THE LAUNCHING PAD

My long time readers know: I'm always on the lookout for hidden stock gems in the hottest sectors – and stem cell stocks are literally scorching right now.

Stocks like Osiris Therapeutics (OSIR) with accomplishments in the Adult Stem Cell field have made early investors rich. Osiris recently soared from \$4.38 to \$27.40 per share.

Yet, that pales in comparison to what Life Stem's stock can do by tackling the myriad of health issues that could be alleviated by these groundbreaking ASC treatment protocols and the company's absolutely brilliant growth strategy.

As I write this Special Report, **Life Stem Genetics (LIFS)** is trading around the \$1 per share level. I see LIFS as one of the "great hidden stock gems" that could return many multiples above its current price range – FAST!

RIGHT NOW below \$2 a share is the key entry-point where early LIFS investors like YOU can expect the largest shareholder gains!

- 1 Roll-out of Growth Strategy
- 2 Key breakthroughs in ASC Therapies
- 3 Sky's the Limit on LIFS's Profit Potential



When you understand what Life Stem has already accomplished and what their revenue projections are, you'll see why I'm so excited to bring this stock to my readers just BEFORE the pending lift-off! **Consider...**

LIFS's distinct Adult Stem Cell harvesting protocol is currently returning rates as high as 1.2 BILLION stem cells per sample – more than 12x the industry high!

LIFS's expert stem cell team has performed 5,000+ ASC treatments and counting – including some of the biggest names from the NBA, NFL, MLB, and PGA!

LIFS's clinics can generate up to \$30 MILLION per year in revenues!

LIFS expects to have more than 140 affiliate and corporate locations in operation throughout the world within 5 years!

LIFS anticipates annual revenues of \$111 MILLION by year-5 followed by continual revenue growth!

MARKET PENETRATION

The industry made an estimated \$73.5 Billion last year. Currently, the top four areas for ASC treatments are neurological disorders, cancer, orthopedic, and dermatology.

RANGE OF ADULT STEM CELL PROCEDURES: Therapeutic Area Market Size

Bone and Joint Disorders	\$2.3 Billion	\$3.5 Billion	\$6.8 Billion
Cancer	\$1.8 Billion	\$3.2 Billion	\$7.5 Billion
Cardiovascular Disorders	\$1.2 Billion	\$2.8 Billion	\$4.9 Billion
Diabetes Mellitus	\$1.2 Billion	\$2.2 Billion	\$5.3 Billion
Hematological Disorders	\$1.7 Billion	\$2.9 Billion	\$5.9 Billion
Liver Disorders	\$1.1 Billion	\$1.8 Billion	\$1.4 Billion
Nuerological Disorders	\$3.3 Billion	\$8.1 Billion	\$19.8 Billion
Skin and Wound Care	\$1 Billion	\$1.7 Billion	\$3.5 Billion
Urinary Incontinence	\$500 Million	\$1 Billion	\$2.3 Billion
Other	\$3.6 Billion	\$4.8 Billion	\$15.1 Billion
Total	\$17.7 BILLION	\$32 BILLION	\$73.5 BILLION
	2002	2007	2012

By focusing on the rapid deployment of its evolutionary Adult Stem Cell protocol via both corporate and affiliate clinics, Life Stem Genetics (**LIFS**) can gain worldwide attention as a leader in the ASC treatment field.

The market in the U.S alone is...in a word...**HUGE!** Yet, Life

Stem's growth strategy gets even better.

"A global approach designed to maximize value for all LIFS Shareholders"

HOW?


First: Life Stem Genetics is building its base of affiliate clinics internationally from the outset. The first clinics outside the U.S. are already being planned for Hong Kong and mainland China. By gaining an international foothold early on starting with Asia, the company should be able to quickly and seamlessly expand into Europe, Canada, and Australia.





Second: Life Stem Genetics is not standing pat on just its groundbreaking Adult Stem Cell treatments. The company is already offering highly-profitable, value added treatments including: Platelet Rich Plasma Therapies, Quality Nutraceutical and Medical Supplements, IV Nutritional Cocktails, Stem Cell Banking for future treatments, and Hyperbaric Oxygen Therapy (HBOT). This should be a huge boost to the company's bottom line.

LIFS: REVENUE PROJECTION (YRS 1 - 5)



**Opportunity: One Major Story in the Press could
Send LIFS Up...Up...Up!**

**We're Not the Only Ones Who Realize the Value
of Solving Human Disease through ASC Therapies**

I think of all that Life Stem Genetics (LIFS) has accomplished - and then I remember this stock is trading around \$1 per share at the time of this writing. It's exciting to me that one of humanity's greatest opportunities can also be one of the most profitable investments - EVER.

I don't have to tell you what success means in the field of Adult Stem Cell therapies. The potential to successfully treat and potentially cure some of the most debilitating diseases known to man can translate to life-changing gains for well-timed, properly positioned investors.

**I See Potential in Life Stem's Stock to Enable You
to Retire Years Earlier than You Planned**

I believe that if you let this opportunity pass you by, you'll regret it for years to come. Every time you hear about Life Stem Genetics (LIFS), you'll think, "Man, I should have..." And that's something I want you to instinctively avoid.

Rarely am I this enthusiastic about a stock - but LIFS has Huge Upside Potential written all over it. Just like Ultra Petroleum did at \$2 before my readers watched it soar to over \$200 per share pre-split!

Life Stem has every indicator of being our next Ultra success story. I recommend you begin picking up LIFS shares now up to our initial \$2 buy-ceiling. Buy only what you're comfortable with and then watch it. I'm confident you'll soon be adding to your position once



you see the immense profit potential in-play.

The Next Move Is YOURS...

Timing is everything in the stock market. Wall Street operates on a "herd" mentality. Once they see something big, they all rush in at the same time. Yet, I've always said that the largest shareholder gains go to those with the foresight to buy early BEFORE the secret's out - when the share-price is still at bargain basement prices. **That time is NOW.**

Sincerely on the Contrary,



Scott Fraser, Editor The Natural Contrarian

Symbol: **LIFS**

Initial Buy: **IMMEDIATELY**

Secondary Buy: **\$2 to \$5**

Long Term Target: **\$ Infinite***

**Because the projected return on investment of the global stem cell industry is already in the \$Billions, I'll wait to put a specific price target on Life Stem Genetics (LIFS) so I don't have to keep raising it. Now is the time to make your initial buy on LIFS. Our initial valuation of Life Stem's future market share is well above the current near \$1 price level and increasing.*

CONTRARIAN WEALTH COALITION

We Have YOUR Profit-Key with a 100% Guarantee!

YES, FINALLY... No More Buying High then Selling Low!

There is only 1 mistake you can make in the stock market: Buying High then Selling Low. Our guidance system ensures you avoid that mistake and then **PROFIT** on the predictable frenzy. Plus, as part of your membership, you'll receive other undiscovered stock opportunities like **Life Stem Genetics (LIFS)** plus breaking **Compass Alerts** on YOUR stocks!

Here is how to order:

Click on the below link and select your preferred subscription:

- ➔ **Best Savings!** 24-month membership, just **\$297**. Includes 24/7 access to our world-renowned Stock-Profit Compass for 2 years. A \$700 value. **You save over \$400!**
- ➔ **Great Value!** 12-month membership, just **\$165**. Includes 24/7 access to our world-renowned Stock-Profit Compass for 1 year. A \$350 value. **You save \$185!**

CLICK HERE

to join our **Contrarian Wealth Coalition**

100% Guarantee! Cancel anytime during your membership for a full refund – but understand this: We haven't had a refund request in over 3 years! Our proprietary playbooks are too profitable!

Your Contrarian Wealth Coalition Membership Includes:

- ✓ 24/7 Access to our Stock-Profit Compass PLUS Signals on YOUR Stocks
- ✓ All-Access Pass to Natural Contrarian and Situational Strategies Newsletters
- ✓ Secret Trade Alerts - sent via courier
- ✓ Situational Strategy Templates + Breaking Stock Updates
- ✓ Exclusive Bargain-Season Buying Guide



This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. Information is obtained from sources believed to be reliable, but the information cannot be guaranteed as to its accuracy or completeness. The publisher is not, and does not purport to be, a registered investment adviser and did not accept compensation in return for this commentary. The objective of this new sletter is to present Situational Analysis and to provide progressive implementation of the author's proprietary Situational Strategy Templates. No statement or expression of opinion, or any other matter herein, directly or indirectly, shall be construed as an offer to sell or the solicitation of an offer to buy the securities mentioned. Readers should not view this publication as offering personalized investment advice, and must individually determine the suitability of investments discussed for inclusion in their own portfolio. Past performance does not guarantee future results. Reprints or redistribution of this copyrighted material is allowed only by written permission from Contrarian Press LLC.